HRP20200887T1 - Smjese za inhibiciju masp-2 ovisne aktivacije komplementa - Google Patents
Smjese za inhibiciju masp-2 ovisne aktivacije komplementa Download PDFInfo
- Publication number
- HRP20200887T1 HRP20200887T1 HRP20200887TT HRP20200887T HRP20200887T1 HR P20200887 T1 HRP20200887 T1 HR P20200887T1 HR P20200887T T HRP20200887T T HR P20200887TT HR P20200887 T HRP20200887 T HR P20200887T HR P20200887 T1 HRP20200887 T1 HR P20200887T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- masp
- fragment
- antigen
- nucleic acid
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 230000000295 complement effect Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 claims 9
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 claims 4
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 claims 1
- -1 according to claim 1 Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000054960 human MASP2 Human genes 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
1. Izolirano humano monoklonsko protutijelo, ili njegov antigen vezujući fragment, koji veže humani MASP-2 i inhibira MASP-2 ovisnu aktivaciju komplementa, pri čemu protutijelo ili njegov antigen vezujući fragment sadrži:
a) varijabilno područje teškog lanca koji sadrži aminokiselinu navedenu u SEQ ID NO: 20; i
b) varijabilno područje lakog lanca koji sadrži aminokiselinsku sekvencu navedenu u SEQ ID NO: 24.
2. Protutijelo ili njegov fragment sukladno zahtjevu 1, pri čemu su protutijelo ili njegov antigen vezujući fragment izabrani iz skupine sastavljene od Fv, Fab, Fab’, F(ab)2, F(ab’)2, jednolančanog protutijela, ScFv, univalentnog protutijela kojem nedostaje područje zgloba i cijelog protutijela.
3. Protutijelo ili njegov fragment sukladno zahtjevu 1, pri čemu je navedeno protutijelo izabrano iz skupine sastavljene od IgG2 molekula, i IgG1 molekula i IgG4 molekula.
4. Protutijelo ili njegov fragment sukladno zahtjevu 3, pri čemu IgG4 molekula sadrži S228P mutaciju.
5. Molekula nukleinske kiseline koji kodira aminokiselinsku sekvencu MASP-2 protutijela, ili njegov antigen vezujući fragment, sukladno zahtjevu 1.
6. Ekspresijska traka koja sadrži molekulu nukleinske kiseline koji kodira MASP-2 protutijelo sukladno pronalasku u patentnom zahtjevu 5.
7. Stanica koja sadrži najmanje jednu od molekula nukleinske kiseline koji kodiraju MASP-2 protutijelo sukladno zahtjevu 1, sukladno zahtjevu 5 ili zahtjevu 6.
8. Postupak za generiranje izoliranje anti-MASP-2 protutijela koji sadrži kultivaciju stanice sukladno zahtjevu 7 pod uvjetima koji dozvoljavaju ekspresiju molekula nukleinske kiseline koji kodiraju anti-MASP-2 protutijelo sukladno zahtjevu 1 i izoliranje navedenog anti-MASP-2 protutijela.
9. Farmaceutski sastav koja sadrži humano monoklonsko anti-MASP-2 protutijelo, ili njegov fragment, sukladno zahtjevu 1, i farmaceutski prihvatljiv ekscipijens.
10. Farmaceutski sastav sukladno zahtjevu 9, pri čemu je sastav formuliran za intra-arterijsku, intravensku, intrakranijalnu, intramuskularnu, inhalacijsku, nazalnu ili subkutanu primjenu.
11. Farmaceutski sastav sukladno zahtjevu 9 koja sadrži jediničnu dozu od 1 mg do 1000 mg izoliranog protutijela ili njegovog fragmenta sukladno zahtjevu 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161482567P | 2011-05-04 | 2011-05-04 | |
PCT/US2012/036509 WO2012151481A1 (en) | 2011-05-04 | 2012-05-04 | Compositions for inhibiting masp-2 dependent complement acitivation |
EP12779347.9A EP2704743B1 (en) | 2011-05-04 | 2012-05-04 | Compositions for inhibiting masp-2 dependent complement acitivation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200887T1 true HRP20200887T1 (hr) | 2020-09-04 |
Family
ID=47090380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200887TT HRP20200887T1 (hr) | 2011-05-04 | 2020-06-02 | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa |
Country Status (25)
Country | Link |
---|---|
US (6) | US9011860B2 (hr) |
EP (2) | EP3725811A3 (hr) |
JP (5) | JP5891298B2 (hr) |
KR (3) | KR101641057B1 (hr) |
CN (2) | CN107011443B (hr) |
AU (1) | AU2012250627B2 (hr) |
BR (1) | BR112013028429B1 (hr) |
CA (3) | CA3131223C (hr) |
CL (1) | CL2013003140A1 (hr) |
CY (1) | CY1123212T1 (hr) |
DK (1) | DK2704743T3 (hr) |
ES (1) | ES2795667T3 (hr) |
HR (1) | HRP20200887T1 (hr) |
HU (1) | HUE049154T2 (hr) |
IL (4) | IL229208B (hr) |
LT (1) | LT2704743T (hr) |
ME (1) | ME03755B (hr) |
MX (3) | MX361175B (hr) |
PL (1) | PL2704743T3 (hr) |
PT (1) | PT2704743T (hr) |
RS (1) | RS60541B1 (hr) |
RU (3) | RU2636038C2 (hr) |
SI (1) | SI2704743T1 (hr) |
WO (1) | WO2012151481A1 (hr) |
ZA (1) | ZA201308943B (hr) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008304778B9 (en) | 2007-09-26 | 2014-05-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
CA3237802A1 (en) | 2011-04-08 | 2012-10-11 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
MX361175B (es) * | 2011-05-04 | 2018-11-29 | Omeros Corp | Composiciones para inhibir la activación del complemento dependiente de la masp-2. |
EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE |
CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
HRP20220637T1 (hr) | 2012-11-02 | 2022-06-24 | Bioverativ Usa Inc. | Protutijela anti-komplementa c1s i njihova upotreba |
US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
NZ729747A (en) * | 2013-03-15 | 2020-03-27 | Omeros Corp | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
HUE051746T2 (hu) * | 2013-10-17 | 2021-03-29 | Omeros Corp | Eljárások MASP-2-függõ komplement aktiválással kapcsolatos állapotok kezelésére |
UA127961C2 (uk) | 2014-12-19 | 2024-02-28 | Чугей Сейяку Кабусікі Кайся | Антитіло до латентного міостатину |
JP2018510842A (ja) | 2015-02-05 | 2018-04-19 | 中外製薬株式会社 | イオン濃度依存的抗原結合ドメインを含む抗体、Fc領域改変体、IL−8に結合する抗体、およびその使用 |
EA201792080A1 (ru) | 2015-04-06 | 2018-03-30 | БИОВЕРАТИВ ЮЭсЭй ИНК. | Гуманизированные анти-c1s антитела и способы их применения |
CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
IL259225B (en) | 2015-11-09 | 2022-09-01 | Omeros Corp | Preparations containing antibodies that suppress masp-2 and antigen-binding fragments for use in the treatment of tma associated with hematopoietic stem cell transplantation |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
CN117503923A (zh) | 2016-01-05 | 2024-02-06 | 莱斯特大学 | 用于抑制有需要的受试者的纤维化的方法 |
WO2017173290A1 (en) | 2016-03-31 | 2017-10-05 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
TWI831965B (zh) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Il-8相關疾病之治療用或預防用組成物 |
JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
TW202402809A (zh) * | 2017-08-15 | 2024-01-16 | 美商歐米諾斯公司 | 用於治療和/或預防與造血幹細胞移植有關的移植物抗宿主病和/或瀰漫性肺泡出血和/或靜脈閉塞性病的方法 |
WO2019040453A1 (en) * | 2017-08-25 | 2019-02-28 | Omeros Corporation | HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME |
WO2019177543A1 (en) | 2018-03-15 | 2019-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
BR112020024148A2 (pt) * | 2018-05-29 | 2021-03-30 | Omeros Corporation | Compostos, composição farmacêutica, e, métodos para identificação de uma pequena molécula capaz de inibir masp-2 e para o tratamento de uma doença ou transtorno associado a masp-2 |
CA3159172A1 (en) * | 2019-12-04 | 2021-06-10 | Michael Cicirelli | Masp-2 inhibitors and methods of use |
EP4069678A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
AU2020395306A1 (en) | 2019-12-04 | 2022-06-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
CA3159176A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
TWI834025B (zh) * | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
CN114634575A (zh) * | 2020-12-16 | 2022-06-17 | 康诺亚生物医药科技(成都)有限公司 | 一种补体抑制剂的开发和应用 |
MX2023008834A (es) * | 2021-02-05 | 2023-09-14 | Omeros Corp | Biomarcador para evaluar el riesgo de desarrollar covid-19 agudo y covid-19 post-agudo. |
CN115215937B (zh) * | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
AU2022263683A1 (en) | 2021-04-25 | 2023-11-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof |
US20230265215A1 (en) | 2021-12-10 | 2023-08-24 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
WO2023103789A1 (zh) * | 2021-12-10 | 2023-06-15 | 舒泰神(北京)生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
CN116284412A (zh) * | 2021-12-21 | 2023-06-23 | 沈阳三生制药有限责任公司 | 一种抗masp-2抗体及其制备方法与用途 |
WO2023174039A1 (en) * | 2022-03-18 | 2023-09-21 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | Masp-2-targetting antibodies and uses thereof |
US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのmaspに対するモノクローナル抗体 |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
CA2347734A1 (en) | 1998-12-15 | 2000-06-22 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
CN101850120A (zh) | 1999-07-21 | 2010-10-06 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
US20010051754A1 (en) | 1999-08-03 | 2001-12-13 | Daria N. Lissy | Plural stage toluene disproportionation process minimizing ethylbenzene |
EP1259547B1 (en) * | 2000-03-01 | 2012-07-11 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
NZ523900A (en) * | 2000-07-13 | 2004-02-27 | Jens Christian Jensenius | Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections |
ES2288900T3 (es) * | 2001-10-05 | 2008-02-01 | Affimed Therapeutics Ag | Anticuerpo de origen humano para inhibir la agregacion de trombocitos. |
EP1461442B1 (en) * | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human ig lambda light chain genes |
CN1697647A (zh) | 2002-02-01 | 2005-11-16 | 奥默罗斯公司 | 用于抑制疼痛,炎症和软骨退化的溶液及方法 |
CN100519643C (zh) | 2002-07-19 | 2009-07-29 | 奥默罗斯公司 | 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料 |
KR20050106459A (ko) * | 2003-02-28 | 2005-11-09 | 미쯔비시 웰 파마 가부시키가이샤 | 단일클론 항체, 이를 코딩하는 유전자, 하이브리도마, 의약조성물 및 진단 시약 |
EP1625166B1 (en) * | 2003-05-12 | 2015-04-08 | Helion Biotech ApS | Antibodies to masp-2 |
US8652477B2 (en) | 2009-10-16 | 2014-02-18 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation |
GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
TR201708554T4 (tr) | 2004-06-10 | 2019-02-21 | Omeros Corp | Masp-2 ye bağlı tamamlayıcı aktivasyon ile ilişkili durumların tedavisi için yöntemler. |
AU2009294415B2 (en) * | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
EP2356146A1 (en) * | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
MX361175B (es) * | 2011-05-04 | 2018-11-29 | Omeros Corp | Composiciones para inhibir la activación del complemento dependiente de la masp-2. |
NZ781091A (en) * | 2012-04-06 | 2022-04-29 | Omeros Corp | Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria |
-
2012
- 2012-05-04 MX MX2017006060A patent/MX361175B/es unknown
- 2012-05-04 PT PT127793479T patent/PT2704743T/pt unknown
- 2012-05-04 CN CN201710201126.9A patent/CN107011443B/zh active Active
- 2012-05-04 HU HUE12779347A patent/HUE049154T2/hu unknown
- 2012-05-04 KR KR1020137032078A patent/KR101641057B1/ko active Application Filing
- 2012-05-04 CA CA3131223A patent/CA3131223C/en active Active
- 2012-05-04 EP EP19215429.2A patent/EP3725811A3/en active Pending
- 2012-05-04 WO PCT/US2012/036509 patent/WO2012151481A1/en active Application Filing
- 2012-05-04 CA CA2832871A patent/CA2832871C/en active Active
- 2012-05-04 PL PL12779347T patent/PL2704743T3/pl unknown
- 2012-05-04 DK DK12779347.9T patent/DK2704743T3/da active
- 2012-05-04 JP JP2014509474A patent/JP5891298B2/ja active Active
- 2012-05-04 CN CN201280032866.XA patent/CN103687620B/zh active Active
- 2012-05-04 KR KR1020187021028A patent/KR102024016B1/ko active IP Right Grant
- 2012-05-04 ME MEP-2020-121A patent/ME03755B/me unknown
- 2012-05-04 CA CA3025762A patent/CA3025762C/en active Active
- 2012-05-04 RS RS20200685A patent/RS60541B1/sr unknown
- 2012-05-04 KR KR1020167018831A patent/KR101882830B1/ko active IP Right Grant
- 2012-05-04 RU RU2013153527A patent/RU2636038C2/ru active
- 2012-05-04 SI SI201231793T patent/SI2704743T1/sl unknown
- 2012-05-04 LT LTEP12779347.9T patent/LT2704743T/lt unknown
- 2012-05-04 AU AU2012250627A patent/AU2012250627B2/en active Active
- 2012-05-04 BR BR112013028429-3A patent/BR112013028429B1/pt active IP Right Grant
- 2012-05-04 ES ES12779347T patent/ES2795667T3/es active Active
- 2012-05-04 EP EP12779347.9A patent/EP2704743B1/en active Active
- 2012-05-04 US US13/464,334 patent/US9011860B2/en active Active
- 2012-05-04 MX MX2013012862A patent/MX347691B/es active IP Right Grant
- 2012-11-03 IL IL229208A patent/IL229208B/en active IP Right Grant
-
2013
- 2013-10-30 CL CL2013003140A patent/CL2013003140A1/es unknown
- 2013-11-03 IL IL229208A patent/IL229208A0/en unknown
- 2013-11-04 MX MX2018014714A patent/MX2018014714A/es unknown
- 2013-11-27 ZA ZA2013/08943A patent/ZA201308943B/en unknown
-
2015
- 2015-03-17 US US14/660,040 patent/US9475885B2/en active Active
- 2015-09-09 JP JP2015177337A patent/JP6352226B2/ja active Active
-
2016
- 2016-09-13 US US15/263,876 patent/US10047165B2/en active Active
-
2017
- 2017-10-31 RU RU2017137872A patent/RU2725958C2/ru active
-
2018
- 2018-04-04 JP JP2018072245A patent/JP6669800B2/ja active Active
- 2018-07-13 US US16/034,896 patent/US10683367B2/en active Active
-
2019
- 2019-05-20 IL IL266756A patent/IL266756B/en unknown
-
2020
- 2020-02-27 JP JP2020031661A patent/JP2020097630A/ja not_active Withdrawn
- 2020-04-24 US US16/857,558 patent/US11613589B2/en active Active
- 2020-06-02 HR HRP20200887TT patent/HRP20200887T1/hr unknown
- 2020-06-10 CY CY20201100525T patent/CY1123212T1/el unknown
- 2020-06-22 RU RU2020120539A patent/RU2020120539A/ru unknown
-
2021
- 2021-08-10 IL IL285522A patent/IL285522A/en unknown
-
2022
- 2022-09-02 JP JP2022139872A patent/JP2022172275A/ja active Pending
-
2023
- 2023-02-13 US US18/168,192 patent/US20240092938A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200887T1 (hr) | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa | |
RU2711141C2 (ru) | Антитела против pd-1 | |
US20230399388A1 (en) | Methods for treating inflammation using antibodies to kallidin and des-arg10-kallidin | |
JP6022515B2 (ja) | 抗a型インフルエンザウイルス中和抗体およびその使用 | |
JP2020073571A (ja) | Pd−l1に結合する抗原結合蛋白質 | |
HRP20201595T1 (hr) | Anti-pd-l1 protutijela i njihova uporaba | |
HRP20171315T1 (hr) | Optimizacija humanih antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
CA3039140A1 (en) | Anti-lag-3 antibodies and compositions | |
IL299072A (en) | Antibodies and methods for using them | |
AU2017233121A1 (en) | Multispecific Fab fusion proteins and use thereof | |
IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
JP2015500207A5 (hr) | ||
HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
JP2016538876A5 (hr) | ||
US10836823B2 (en) | Dsg2 monoclonal antibody and the applications thereof | |
RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
US20220033491A1 (en) | Combination therapy of cldn18 antibody and chemotherapy drugs | |
TW201609810A (zh) | 非糖苷基抗-tweakr抗體及其用途 | |
WO2016075546A2 (en) | Antibodies that neutralize ebola virus and uses thereof | |
US20240101674A1 (en) | Pd1 and vegfr2 dual-binding agents | |
RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
AU2013202434B2 (en) | Dengue virus neutralizing antibodies and uses thereof | |
RU2022101756A (ru) | Антитела к tigit и их применение | |
Li et al. | Antibodies to kallidin and des-Arg 9-kallidin | |
JPWO2021069670A5 (hr) |